Summary of InMode Conference Call Company Overview - **Company**: InMode - **Industry**: Medical Devices, specifically in aesthetic treatments Key Points Current Operational Challenges - InMode is currently operating at approximately **60% manufacturing capacity** due to regional instability and threats from neighboring countries [5][6] - The company faces significant **logistical challenges** with shipping, as major carriers like DHL and FedEx are not operating flights to Israel, leading to increased shipping costs [6][7] - Employee attendance is affected by school closures, impacting workforce availability [6] Inventory Management - InMode has built a **safety inventory** of finished goods and components over the past two years, which is currently being utilized to meet market demands despite shipping challenges [11] - The company has shipped products to subsidiaries globally to fill gaps caused by local disruptions [11] Share Buyback Program - InMode has executed a **share buyback program**, purchasing shares worth **$508 million** to date, with an additional **$85 million to $90 million** approved for buyback, totaling around **$600 million** over the last 3.5 years [14][15] - The company aims to maintain liquidity for potential M&A opportunities, targeting acquisitions in the range of **$500 million to $1 billion** [17] Market Trends and Customer Insights - There is a **stabilization** in patient activity and treatment usage, with no significant growth or decline observed [19] - High interest rates on leasing (14%-15%) are affecting customer purchasing decisions, particularly in the U.S. market [20] - The company anticipates potential growth in 2027, contingent on stabilization in 2026 and new product launches [22][33] Product and Technology Development - InMode is focusing on expanding its portfolio to include **non-invasive technologies**, which now contribute nearly **20%** to its revenue [34] - The company is developing new laser technologies to complement its existing RF energy products, aiming for a competitive edge in the market [36][39] - A dedicated team for the **dry eye treatment** platform has been established, with plans to submit for FDA approval for a new RF-based study [41][42] Geographic and Structural Changes - InMode has restructured its North American operations to unify management, aiming for improved efficiency and sales performance [29][30] - The company is also exploring growth opportunities in Asia, particularly in China and Korea, where it currently has limited market presence [46][47] Financial Outlook - Gross margins are impacted by a shift towards more laser-based devices, which traditionally have lower margins, and by tariffs affecting U.S. operations [49][50] - Despite current challenges, there is optimism about the recovery of demand for aesthetic procedures, which is expected to improve margins in the future [51] Additional Insights - The company is cautious about future guidance due to macroeconomic uncertainties and ongoing regional instability [22][50] - InMode's management is actively monitoring the effectiveness of recent organizational changes and is prepared to make further adjustments as necessary [30][32]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $103.9 million, up from $97.9 million in Q4 2024, while full-year revenue totaled $370.5 million, a 6% decrease compared to 2024 [8][9] - Gross margins for Q4 2025 were 78% on a GAAP basis, down from 79% in Q4 2024, while non-GAAP gross margins were 79% for both Q4 and full year 2025 [9][11] - GAAP diluted earnings per share for Q4 were $0.42, compared to $1.14 in Q4 2024, and $1.43 for the full year 2025, down from $2.25 in 2024 [11][12] Business Line Data and Key Metrics Changes - Revenue from consumables and services increased slightly compared to last year, indicating early signs of stabilization in patient activity [4] - Minimally invasive technology platforms accounted for 76% of total revenues in Q4 2025, while consumables and services represented 22% of revenue, up from 20% in 2024 [9][10] Market Data and Key Metrics Changes - Sales outside the U.S. totaled $48.5 million in Q4 2025, representing 47% of total sales and a 38% increase compared to Q4 2024, driven primarily by Europe [9] - For the full year 2025, sales outside the U.S. accounted for $171.8 million, or 46% of total sales, a 15% increase compared to 2024 [9] Company Strategy and Development Direction - The company views 2026 as a stabilization year following a prolonged period of industry softness, with expectations for revenue to be broadly in line with 2025 [4][7] - Product innovation is a key pillar of the strategy, with plans to launch two new platforms in 2026, including a Korean-made Pico laser device and a device combining new Morpheus technology with Erbium YAG laser [6][7] - The sales force is now segmented across aesthetic and wellness, with a dedicated team for specific platforms to drive increased penetration and improve sales productivity [5] Management's Comments on Operating Environment and Future Outlook - Management noted that the industry has not yet fully recovered from the global economic slowdown, with demand in North America remaining below historical levels, but there are early signs of stabilization in the U.S. and gradual improvement in Europe [7] - The CEO mentioned that interest rates starting to come down could positively impact leasing packages for capital equipment purchases, which may encourage more sales [16] Other Important Information - The company returned $127.4 million to shareholders through a disciplined share repurchase program [12] - The board of directors is exploring strategic alternatives to improve company value, having engaged Bank of America for assistance [19] Q&A Session Summary Question: What signs suggest improving trends in the market? - Management noted a slight increase in procedures and sales in consumables, along with declining interest rates as positive indicators [16] Question: Can you provide updates on strategic alternatives? - The board is considering several strategic alternatives to enhance company value, with management not directly involved in the process [19] Question: What are the expectations for gross margins and EBIT margins? - Management indicated that new product launches, particularly lasers, may impact gross margins, and guidance is conservative based on past experiences [27][28] Question: How significant is the laser market for future growth? - The CEO emphasized that laser platforms are essential for growth, despite being in a saturated market with lower margins compared to existing products [31][32] Question: What is the status of the dry eye indication and FDA approval timelines? - The company is working on FDA approval for a bipolar RF device for dry eye treatment, with studies expected to last through 2026 and possibly into 2027 [64][65]

Summary of InMode (INMD) Conference Call - May 19, 2025 Company Overview - InMode is an Israeli-based company specializing in medical aesthetic equipment, particularly surgical equipment that penetrates the skin [2][3] - Established around 16 years ago, with R&D and manufacturing based in Israel [2] - The company went public in February 2019 at $7 per share and has since seen significant revenue growth [8] Financial Performance - Revenue reached approximately $495 million in 2023, up from $22 million in 2017 [5][6] - Experienced a 20% revenue decline in 2024 due to economic slowdown and increased interest rates [10] - Target for 2025 is to match 2024 revenue levels [10] Product and Technology - InMode's technology includes radio frequency-assisted lipolysis and bipolar Matrix RF (Morpheus) [4][6] - The company has diversified its product line to include applications for urinary incontinence, overactive bladder, and facial rejuvenation [6] - Currently has about 12 platforms in its product portfolio, selling in 90 countries [7] Market Dynamics - The U.S. market constitutes 50% of the business, with the rest coming from international markets [19] - The company faces stronger headwinds in the U.S. compared to international markets, with consumer confidence being a significant issue [22][27] - The first quarter is typically the slowest, with Q2 expected to be stronger [30] Operational Challenges - The ongoing conflict in Israel has posed challenges, but the company has managed to maintain operations [12][35] - Tariff exposure is estimated to impact gross margins by 2% to 3% due to most products being manufactured in Israel [38][39] Marketing and Sales Strategy - The company spends heavily on marketing and sales, with a focus on both B2B and B2C strategies [16][60] - Sales and marketing expenses account for 35% to 40% of revenue, while G&A and R&D expenses are relatively low at around 3% and 4%, respectively [59][60] Future Outlook - The company is optimistic about the recovery of the aesthetic procedure market, although it does not expect an immediate surge in demand [99] - Plans to continue product innovation, with new wellness platforms expected to launch later in 2025 [52] - The management is focused on international expansion, establishing subsidiaries in Argentina and Thailand [71][72] Capital Allocation - In the past 12 months, InMode has repurchased $412 million of its stock, totaling $508 million over two years [85][87] - The company is open to various capital allocation strategies, including further buybacks, M&A, and dividends, depending on market conditions [85][86] Key Risks - Economic slowdown and rising interest rates are significant risks affecting consumer spending on aesthetic procedures [10][22] - The company is closely monitoring inflation trends in both the U.S. and Europe [23] Conclusion - InMode remains a leader in the medical aesthetics market, with a strong focus on innovation and international growth despite current economic challenges [11][72]